Y-MABS THERAPEUTICS INC. - COMMON STOCK

Y-mAbs to Announce Third 2021 Financial and Operating Results on November 4, 2021

28 أكتوبر 2021 16:01:00 بحسب Nasdaq GlobeNewswire

Y-mAbs Announces Data to be Presented at SIOP 2021

16 سبتمبر 2021 09:00:01 بحسب Nasdaq GlobeNewswire

Y-mAbs Announces Priority Review of BLA for DANYELZA® (naxitamab-gqgk) in China

13 سبتمبر 2021 09:00:01 بحسب Nasdaq GlobeNewswire

Y-mAbs to Host Key Opinion Leader Webinar on DANYELZA® (naxitamab-gqgk) Frontline and HITS Data in High-Risk Neuroblastoma

10 سبتمبر 2021 09:00:00 بحسب Nasdaq GlobeNewswire

Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments

05 أغسطس 2021 16:01:01 بحسب Nasdaq GlobeNewswire

Y-mAbs to Announce Second Quarter 2021 Financial and Operating Results on August 5, 2021

29 يوليو 2021 16:05:01 بحسب Nasdaq GlobeNewswire

Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China

06 يوليو 2021 08:37:42 بحسب Nasdaq GlobeNewswire

Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Receives Positive Opinion on Orphan Medicinal Product Designation by EMA

25 يونيو 2021 09:00:00 بحسب Nasdaq GlobeNewswire

Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma

23 يونيو 2021 09:00:01 بحسب Nasdaq GlobeNewswire

Y-mAbs Announces Frontline Data for DANYELZA® (naxitamab-gqgk) in High-Risk Neuroblastoma

04 يونيو 2021 09:05:00 بحسب Nasdaq GlobeNewswire

Y-mAbs Announces Update on Omburtamab for DIPG

04 يونيو 2021 09:00:00 بحسب Nasdaq GlobeNewswire

Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA® (naxitamab-gqgk) and Omburtamab in Latin America

19 مايو 2021 16:01:00 بحسب Nasdaq GlobeNewswire

Y-mAbs Announces Update on SADA Technology

13 مايو 2021 09:00:02 بحسب Nasdaq GlobeNewswire

Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments

06 مايو 2021 16:01:02 بحسب Nasdaq GlobeNewswire

Y-mAbs to Announce First Quarter 2021 Financial and Operating Results on May 6, 2021

29 أبريل 2021 16:01:00 بحسب Nasdaq GlobeNewswire

Y-mAbs Announces Data to be Presented at 2021 ASCO Annual Meeting

29 أبريل 2021 09:00:02 بحسب Nasdaq GlobeNewswire

Y-mAbs Submits Omburtamab Marketing Authorization Application to the European Medicines Agency

27 أبريل 2021 16:01:00 بحسب Nasdaq GlobeNewswire

Y-mAbs Provides Regulatory Update on Omburtamab   

20 أبريل 2021 09:00:01 بحسب Nasdaq GlobeNewswire

Y-mAbs Announces GPA33-SADA Data Presented at AACR

12 أبريل 2021 09:00:00 بحسب Nasdaq GlobeNewswire

Y-mAbs Announces 2020 Financial Results and Recent Corporate Developments

25 فبراير 2021 16:01:00 بحسب Nasdaq GlobeNewswire